PLx Pharma Inc banner
P

PLx Pharma Inc
F:1D5A

Watchlist Manager
PLx Pharma Inc
F:1D5A
Watchlist
Price: 0.0005 EUR Market Closed
Market Cap: €210k

PLx Pharma Inc
Inventory

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

PLx Pharma Inc
Inventory Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Inventory CAGR 3Y CAGR 5Y CAGR 10Y
P
PLx Pharma Inc
F:1D5A
Inventory
$3.2m
CAGR 3-Years
N/A
CAGR 5-Years
54%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Inventory
$14.2B
CAGR 3-Years
4%
CAGR 5-Years
9%
CAGR 10-Years
6%
Bristol-Myers Squibb Co
NYSE:BMY
Inventory
$2.7B
CAGR 3-Years
5%
CAGR 5-Years
5%
CAGR 10-Years
8%
Pfizer Inc
NYSE:PFE
Inventory
$10.7B
CAGR 3-Years
6%
CAGR 5-Years
6%
CAGR 10-Years
4%
Merck & Co Inc
NYSE:MRK
Inventory
$6.7B
CAGR 3-Years
4%
CAGR 5-Years
1%
CAGR 10-Years
4%
Eli Lilly and Co
NYSE:LLY
Inventory
$13.7B
CAGR 3-Years
47%
CAGR 5-Years
28%
CAGR 10-Years
15%
No Stocks Found

PLx Pharma Inc
Glance View

Market Cap
210k EUR
Industry
Pharmaceuticals

PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. The company is headquartered in Sparta, New Jersey and currently employs 16 full-time employees. The company went IPO on 2014-03-13. The firm has two commercialized products, VAZALORE 81 milligram (mg) and VAZALORE 325 mg, which are liquid-filled aspirin capsules for over the counter (OTC) distribution. The firm markets VAZALORE to the healthcare professional and the consumer through several sales and marketing channels. Its product pipeline also includes other oral NSAIDs using the PLxGuard drug delivery platform, including PL1200 Ibuprofen 200 mg and PL1100 Ibuprofen 400 mg, for pain and inflammation in Phase I clinical stage. PLxGuard drug delivery platform employs a pH-dependent release mechanism that relies on association of lipidic excipients with APIs for targeted release in the GI tract.

1D5A Intrinsic Value
Not Available
P

See Also

What is PLx Pharma Inc's Inventory?
Inventory
3.2m USD

Based on the financial report for Sep 30, 2022, PLx Pharma Inc's Inventory amounts to 3.2m USD.

What is PLx Pharma Inc's Inventory growth rate?
Inventory CAGR 5Y
54%

Over the last year, the Inventory growth was 45%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett